Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure Biosciences brings in US$4mln from private placing

Pressure Biosciences has received a further US$745,000 gross from an additional closing of its private placing, taking the total raised to just over US$4mln.
Pressure Biosciences brings in US$4mln from private placing
Pressure , which provides technology for the preparation stage of lab testing in life science research, netted US$670,500 in cash after taking into account fees related to the offering.

Pressure BioSciences (OTCQB:PBIO) received a further US$745,000 gross from an additional closing of its private placing, taking the total raised to just over US$4mln.

The company will issue 1.3mln shares worth of convertible notes, with a fixed price of US$0.28 per share, and warrants, at an exercise price of US$0.40 per share for the additional share purchases.

One or more additional closings are expected in the near future.

Pressure, which provides technology for the preparation stage of lab testing in life science research, netted US$670,500 in cash after taking into account fees related to the offering.

Richard Schumacher, president and chief executive, said the funds will be used for a number of tasks, including to bolster the number of staff in its marketing and sales divisions.

It will use the remainder to boost the firm’s manufacturing capacity, ready for a potential up-listing to a national regulated exchange in the near future, and will enable the company to retire all variable rate convertible debt that had been previously taken on.

PBIO is developing pressure cycling technology-based instruments and consumables for a number of areas in scientific research, including drug discovery and design, cancer and other disease/disorder detection, and the analysis of microorganism populations in soil.

Last week, shares in the stock advanced after it reported a 56% jump in third-quarter revenue, buoyed by solid growth in products and services and grant revenue.

Revenue increased to $580,334 in the July-to-September quarter from $372,545 a year earlier, the South Easton, Massachusetts-based company said.

"We believe PBI has reached a major inflection point," chief executive Schumacher had said.

"We also believe the growth and success shown in 2015 is a bellwether of things to come, and that 2016 will provide breakout well beyond those realized in 2015." 

Shares in the group eased 3.12% to US$0.23.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

couple looking at pregnancy test
November 13 2017
The proceeds from the fundraiser will be used to expand in the People's Republic and will invested in product development
picture of addict
November 16 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
numerous pills
March 24 2018
Genervon is on the lookout for pharma partners to help advance its GM6 drug, which takes aim at a range of deadly diseases hitting the central nervous system

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use